Home > Research > Publications & Outputs > Statistical approaches for the determination of...
View graph of relations

Statistical approaches for the determination of cut points in anti-drug antibody bioassays

Research output: Contribution to journalJournal articlepeer-review

Published

Standard

Statistical approaches for the determination of cut points in anti-drug antibody bioassays. / Schaarschmidt, Frank; Hofmann, M.; Jaki, Thomas; Gruen, B.; Hothorn, Ludwig A.

In: Journal of Immunological Methods, Vol. 418, 03.2015, p. 84-100.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Schaarschmidt, F, Hofmann, M, Jaki, T, Gruen, B & Hothorn, LA 2015, 'Statistical approaches for the determination of cut points in anti-drug antibody bioassays', Journal of Immunological Methods, vol. 418, pp. 84-100. https://doi.org/10.1016/j.jim.2015.02.004

APA

Schaarschmidt, F., Hofmann, M., Jaki, T., Gruen, B., & Hothorn, L. A. (2015). Statistical approaches for the determination of cut points in anti-drug antibody bioassays. Journal of Immunological Methods, 418, 84-100. https://doi.org/10.1016/j.jim.2015.02.004

Vancouver

Schaarschmidt F, Hofmann M, Jaki T, Gruen B, Hothorn LA. Statistical approaches for the determination of cut points in anti-drug antibody bioassays. Journal of Immunological Methods. 2015 Mar;418:84-100. https://doi.org/10.1016/j.jim.2015.02.004

Author

Schaarschmidt, Frank ; Hofmann, M. ; Jaki, Thomas ; Gruen, B. ; Hothorn, Ludwig A. / Statistical approaches for the determination of cut points in anti-drug antibody bioassays. In: Journal of Immunological Methods. 2015 ; Vol. 418. pp. 84-100.

Bibtex

@article{b6852cf56ee649d2bce6ba53459d26c9,
title = "Statistical approaches for the determination of cut points in anti-drug antibody bioassays",
abstract = "Cut points in immunogenicity assays are used to classify future specimens into anti-drug antibody (ADA) positive or negative. To determine a cut point during pre-study validation, drug-naive specimens are often analyzed on multiple microtiter plates taking sources of future variability into account, such as runs, days, analysts, gender, drug-spiked and the biological variability of un-spiked specimens themselves. Five phenomena may complicate the statistical cut point estimation: i) drug-naive specimens may contain already ADA-positives or lead to signals that erroneously appear to be ADA-positive, ii) mean differences between plates may remain after normalization of observations by negative control means, iii) experimental designs may contain several factors in a crossed or hierarchical structure, iv) low sample sizes in such complex designs lead to low power for pre-tests on distribution, outliers and variance structure, and v) the choice between normal and log-normal distribution has a serious impact on the cut point.We discuss statistical approaches to account for these complex data: i) mixture models, which can be used to analyze sets of specimens containing an unknown, possibly larger proportion of ADA-positive specimens, ii) random effects models, followed by the estimation of prediction intervals, which provide cut points while accounting for several factors, and iii) diagnostic plots, which allow the post hoc assessment of model assumptions. All methods discussed are available in the corresponding R add-on package mixADA",
keywords = "Anti-drug antibody, Immunoassays, Immunogenicity, Screening cut point, Software",
author = "Frank Schaarschmidt and M. Hofmann and Thomas Jaki and B. Gruen and Hothorn, {Ludwig A.}",
year = "2015",
month = mar,
doi = "10.1016/j.jim.2015.02.004",
language = "English",
volume = "418",
pages = "84--100",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Statistical approaches for the determination of cut points in anti-drug antibody bioassays

AU - Schaarschmidt, Frank

AU - Hofmann, M.

AU - Jaki, Thomas

AU - Gruen, B.

AU - Hothorn, Ludwig A.

PY - 2015/3

Y1 - 2015/3

N2 - Cut points in immunogenicity assays are used to classify future specimens into anti-drug antibody (ADA) positive or negative. To determine a cut point during pre-study validation, drug-naive specimens are often analyzed on multiple microtiter plates taking sources of future variability into account, such as runs, days, analysts, gender, drug-spiked and the biological variability of un-spiked specimens themselves. Five phenomena may complicate the statistical cut point estimation: i) drug-naive specimens may contain already ADA-positives or lead to signals that erroneously appear to be ADA-positive, ii) mean differences between plates may remain after normalization of observations by negative control means, iii) experimental designs may contain several factors in a crossed or hierarchical structure, iv) low sample sizes in such complex designs lead to low power for pre-tests on distribution, outliers and variance structure, and v) the choice between normal and log-normal distribution has a serious impact on the cut point.We discuss statistical approaches to account for these complex data: i) mixture models, which can be used to analyze sets of specimens containing an unknown, possibly larger proportion of ADA-positive specimens, ii) random effects models, followed by the estimation of prediction intervals, which provide cut points while accounting for several factors, and iii) diagnostic plots, which allow the post hoc assessment of model assumptions. All methods discussed are available in the corresponding R add-on package mixADA

AB - Cut points in immunogenicity assays are used to classify future specimens into anti-drug antibody (ADA) positive or negative. To determine a cut point during pre-study validation, drug-naive specimens are often analyzed on multiple microtiter plates taking sources of future variability into account, such as runs, days, analysts, gender, drug-spiked and the biological variability of un-spiked specimens themselves. Five phenomena may complicate the statistical cut point estimation: i) drug-naive specimens may contain already ADA-positives or lead to signals that erroneously appear to be ADA-positive, ii) mean differences between plates may remain after normalization of observations by negative control means, iii) experimental designs may contain several factors in a crossed or hierarchical structure, iv) low sample sizes in such complex designs lead to low power for pre-tests on distribution, outliers and variance structure, and v) the choice between normal and log-normal distribution has a serious impact on the cut point.We discuss statistical approaches to account for these complex data: i) mixture models, which can be used to analyze sets of specimens containing an unknown, possibly larger proportion of ADA-positive specimens, ii) random effects models, followed by the estimation of prediction intervals, which provide cut points while accounting for several factors, and iii) diagnostic plots, which allow the post hoc assessment of model assumptions. All methods discussed are available in the corresponding R add-on package mixADA

KW - Anti-drug antibody

KW - Immunoassays

KW - Immunogenicity

KW - Screening cut point

KW - Software

U2 - 10.1016/j.jim.2015.02.004

DO - 10.1016/j.jim.2015.02.004

M3 - Journal article

VL - 418

SP - 84

EP - 100

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

ER -